Cargando…
Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks
At the moment, little treatment options are available for Duchenne muscular dystrophy (DMD). The absence of the dystrophin protein leads to a complex cascade of pathogenic events in myofibres, including chronic inflammation and oxidative stress as well as altered metabolism. The attention towards di...
Autores principales: | Boccanegra, Brigida, Verhaart, Ingrid E.C., Cappellari, Ornella, Vroom, Elizabeth, De Luca, Annamaria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261230/ https://www.ncbi.nlm.nih.gov/pubmed/32485610 http://dx.doi.org/10.1016/j.phrs.2020.104917 |
Ejemplares similares
-
LKB1 signaling is altered in skeletal muscle of a Duchenne muscular dystrophy mouse model
por: Boccanegra, Brigida, et al.
Publicado: (2023) -
Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E.C., et al.
Publicado: (2021) -
Growth hormone secretagogues modulate inflammation and fibrosis in mdx mouse model of Duchenne muscular dystrophy
por: Boccanegra, Brigida, et al.
Publicado: (2023) -
The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012) -
Current Pharmacological Strategies for Duchenne Muscular Dystrophy
por: Yao, Shanshan, et al.
Publicado: (2021)